Literature DB >> 27505145

Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients.

Guangjun Song1, Ruifeng Yang1, Huiying Rao1, Bo Feng1, Hui Ma1, Qian Jin1, Lai Wei1.   

Abstract

Early prediction of spontaneous hepatitis B virus e antigen (HBeAg) seroconversion is pivotal in the prevention of unnecessary drug prescription, corresponding financial burden, and adverse reactions. One hundred and thirteen chronic hepatitis B patients with HBeAg-positive in the immune active phase were followed up for about 1.5 years. Patients were classified into two groups: spontaneous HBeAg seroconversion group (group A, n = 18) and non-spontaneous HBeAg seroconversion group. Among the non-spontaneous HBeAg seroconversion group, 35 patients were selected as controls (group B, n = 35). At week 12, there was a significant difference in hepatitis B core-related antigen (HBcrAg) levels between the two groups (group A 4.32 ± 1.05 log10  kU/ml, and group B 5.16 ± 0.53 log10  kU/ml, P = 0.004), and this significance magnified at week 28. Only two variables, HBcrAg level and the reduction in the HBcrAg levels (ΔHBcrAg) at week 28 were enrolled, with the odds ratio of 4.19 and 0.21, respectively. The optimal cutoffs of HBcrAg levels and the ΔHBcrAg at week 28 were 4.90 and 2.00 log10  kU/ml, respectively. The positive predictive value and negative predictive value of HBcrAg levels at week 28 were 73.9% and 96.7%, respectively. The positive predictive value and negative predictive value of the ΔHBcrAg at week 28 were 76.2% and 93.8%, respectively. The measurement of HBcrAg is useful for monitoring the natural course of chronic hepatitis B virus infection. The dynamics of HBcrAg levels could accurately predict the spontaneous HBeAg seroconversion. J. Med. Virol. 89:463-468, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  hepatitis B; hepatitis B core-related antigen; natural history; prediction; spontaneous HBeAg seroconversion

Mesh:

Substances:

Year:  2016        PMID: 27505145     DOI: 10.1002/jmv.24657

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

Review 1.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 2.  Current advances in the elimination of hepatitis B in China by 2030.

Authors:  Shuye Zhang; Fusheng Wang; Zheng Zhang
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

3.  Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Authors:  Carla S Coffin; Scott K Fung; Fernando Alvarez; Curtis L Cooper; Karen E Doucette; Claire Fournier; Erin Kelly; Hin Hin Ko; Mang M Ma; Steven R Martin; Carla Osiowy; Alnoor Ramji; Edward Tam; Jean Pierre Villeneuve
Journal:  Can Liver J       Date:  2018-12-25

4.  Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients.

Authors:  Jun Li; Zhao Wu; Gui-Qiang Wang; Hong Zhao
Journal:  Chin Med J (Engl)       Date:  2021-03-17       Impact factor: 2.628

Review 5.  New perspectives of biomarkers for the management of chronic hepatitis B.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Clin Mol Hepatol       Date:  2016-12-25

Review 6.  Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection.

Authors:  Magda Rybicka; Krzysztof Piotr Bielawski
Journal:  Microorganisms       Date:  2020-09-15

7.  Hepatitis B core-related antigen: Are we near a treatment endpoint?

Authors:  Tarana Gupta
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

Review 8.  Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?

Authors:  Elia Moreno-Cubero; Robert T Sánchez Del Arco; Julia Peña-Asensio; Eduardo Sanz de Villalobos; Joaquín Míquel; Juan Ramón Larrubia
Journal:  World J Gastroenterol       Date:  2018-05-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.